Patient, disease, and transplant characteristics of 133 patients receiving transplants for SAA anemia and comparison of characteristics according to the conditioning regimen with Cy-ATG or Cy-TAI
. | All patients . | . | Patients treated with Cy-TAI . | . | Patients treated with Cy-ATG . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | No. (%) . | No. if ≠ 133 . | No. (%) . | No. if ≠ 100 . | No. (%) . | No. if ≠ 33 . | P* . | |||
| Severe disease at diagnosis | 82 (76) | 108 | 61 (78) | 78 | 21 (70) | 30 | .372 | |||
| Infection within 3 mo before transplantation | 45 (34) | 35 (35) | 10 (30) | .621 | ||||||
| Specific treatment before transplantation | 67 (50) | 51 (51) | 16 (48) | .802 | ||||||
| ATG | 32 (48) | 67 | 25 (49) | 51 | 7 (44) | 16 | .713 | |||
| CsA | 17 (25) | 67 | 5 (10) | 51 | 12 (75) | 16 | < .001 | |||
| Androgens | 39 (58) | 67 | 38 (75) | 51 | 1 (6) | 16 | < .001 | |||
| Female sex | 53 (40) | 40 (40) | 13 (39) | .951 | ||||||
| Female donor/male recipient | 35 (27) | 132 | 26 (26) | 9 (28) | 32 | .813 | ||||
| Recipient age at transplantation, y | .621 | |||||||||
| Younger than 15 | 50 (38) | 39 (39) | 11 (33) | |||||||
| 15-20 | 23 (17) | 19 (19) | 4 (12) | |||||||
| 20-30 | 36 (27) | 25 (25) | 11 (33) | |||||||
| Older than 30 | 24 (18) | 17 (17) | 7 (21) | |||||||
| Interval from diagnosis to transplantation less than 1 y | 109 (83) | 132 | 81 (82) | 99 | 28 (85) | .691 | ||||
| ABO incompatibility | .813 | |||||||||
| Absence | 102 (77) | 78 (78) | 24 (73) | |||||||
| Minor | 20 (15) | 14 (14) | 6 (18) | |||||||
| Major | 11 (8) | 8 (8) | 3 (9) | |||||||
| GvHD prophylaxis | < .001 | |||||||||
| MTX alone | 17 (13) | 17 (17) | 0 (0) | |||||||
| CsA alone | 46 (35) | 46 (46) | 0 (0) | |||||||
| CsA and MTX | 70 (53) | 37 (37) | 33 (100) | |||||||
. | All patients . | . | Patients treated with Cy-TAI . | . | Patients treated with Cy-ATG . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | No. (%) . | No. if ≠ 133 . | No. (%) . | No. if ≠ 100 . | No. (%) . | No. if ≠ 33 . | P* . | |||
| Severe disease at diagnosis | 82 (76) | 108 | 61 (78) | 78 | 21 (70) | 30 | .372 | |||
| Infection within 3 mo before transplantation | 45 (34) | 35 (35) | 10 (30) | .621 | ||||||
| Specific treatment before transplantation | 67 (50) | 51 (51) | 16 (48) | .802 | ||||||
| ATG | 32 (48) | 67 | 25 (49) | 51 | 7 (44) | 16 | .713 | |||
| CsA | 17 (25) | 67 | 5 (10) | 51 | 12 (75) | 16 | < .001 | |||
| Androgens | 39 (58) | 67 | 38 (75) | 51 | 1 (6) | 16 | < .001 | |||
| Female sex | 53 (40) | 40 (40) | 13 (39) | .951 | ||||||
| Female donor/male recipient | 35 (27) | 132 | 26 (26) | 9 (28) | 32 | .813 | ||||
| Recipient age at transplantation, y | .621 | |||||||||
| Younger than 15 | 50 (38) | 39 (39) | 11 (33) | |||||||
| 15-20 | 23 (17) | 19 (19) | 4 (12) | |||||||
| 20-30 | 36 (27) | 25 (25) | 11 (33) | |||||||
| Older than 30 | 24 (18) | 17 (17) | 7 (21) | |||||||
| Interval from diagnosis to transplantation less than 1 y | 109 (83) | 132 | 81 (82) | 99 | 28 (85) | .691 | ||||
| ABO incompatibility | .813 | |||||||||
| Absence | 102 (77) | 78 (78) | 24 (73) | |||||||
| Minor | 20 (15) | 14 (14) | 6 (18) | |||||||
| Major | 11 (8) | 8 (8) | 3 (9) | |||||||
| GvHD prophylaxis | < .001 | |||||||||
| MTX alone | 17 (13) | 17 (17) | 0 (0) | |||||||
| CsA alone | 46 (35) | 46 (46) | 0 (0) | |||||||
| CsA and MTX | 70 (53) | 37 (37) | 33 (100) | |||||||